Search

Your search keyword '"Bollig, Claudia"' showing total 36 results
Start Over Author "Bollig, Claudia"

Refine your results

more »

more »

more »
36 results on '"Bollig, Claudia"'

1. Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials

Author

Alawadhi, Solaf, Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Boutron, Isabelle, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Cohen-Boulakia, Sarah, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Ferrand, Gabriel, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J., Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Ravaud, Philippe, Ripoll, Pierre, Riveros, Carolina, Rivière, Philippe, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Vuillemot, Romain, Xia, Jun, Yu, Xuan, Zoletic, Emina, Zweigenbaum, Pierre, Nguyen, Van Thu, and Barnier, Julien

Published
2021
Full Text
View/download PDF

3. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT

Author

Schünemann, Holger J., Wiercioch, Wojtek, Brozek, Jan, Etxeandia-Ikobaltzeta, Itziar, Mustafa, Reem A., Manja, Veena, Brignardello-Petersen, Romina, Neumann, Ignacio, Falavigna, Maicon, Alhazzani, Waleed, Santesso, Nancy, Zhang, Yuan, Meerpohl, Jörg J., Morgan, Rebecca L., Rochwerg, Bram, Darzi, Andrea, Rojas, Maria Ximenas, Carrasco-Labra, Alonso, Adi, Yaser, AlRayees, Zulfa, Riva, John, Bollig, Claudia, Moore, Ainsley, Yepes-Nuñez, Juan José, Cuello, Carlos, Waziry, Reem, and Akl, Elie A.

Published
2017
Full Text
View/download PDF

5. Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials

Author

Nguyen, Van Thu, Rivière, Philippe, Ripoll, Pierre, Barnier, Julien, Vuillemot, Romain, Ferrand, Gabriel, Cohen-Boulakia, Sarah, Ravaud, Philippe, Boutron, Isabelle, Alawadhi, Solaf, Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J., Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Riveros, Carolina, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Xia, Jun, Yu, Xuan, Zoletic, Emina, and Zweigenbaum, Pierre

Subjects
Epidemiology
Abstract

Objectives: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated. Study Design and Setting: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered. Results: By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1–Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33–67]; 15–163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients. Conclusion: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.

Published
2021
Full Text
View/download PDF

6. Interleukin-6 blocking agents for treating COVID-19: a living systematic review

Author

Ghosn, Lina, additional, Chaimani, Anna, additional, Evrenoglou, Theodoros, additional, Davidson, Mauricia, additional, Graña, Carolina, additional, Schmucker, Christine, additional, Bollig, Claudia, additional, Henschke, Nicholas, additional, Sguassero, Yanina, additional, Nejstgaard, Camilla Hansen, additional, Menon, Sonia, additional, Nguyen, Thu Van, additional, Ferrand, Gabriel, additional, Kapp, Philipp, additional, Riveros, Carolina, additional, Ávila, Camila, additional, Devane, Declan, additional, Meerpohl, Joerg J, additional, Rada, Gabriel, additional, Hróbjartsson, Asbjørn, additional, Grasselli, Giacomo, additional, Tovey, David, additional, Ravaud, Philippe, additional, and Boutron, Isabelle, additional

Published
2021
Full Text
View/download PDF

9. Evidence gap on antihyperglycemic pharmacotherapy in frail older adults : A systematic review

Author

Bollig, Claudia, Torbahn, Gabriel, Bauer, Jürgen, Brefka, Simone, Dallmeier, Dhayana, Denkinger, Michael, Eidam, Annette, Klöppel, Stefan, Zeyfang, Andrej, and Voigt-Radloff, Sebastian

Subjects
610 Medicine & health
Abstract

BACKGROUND Although antihyperglycemic pharmacotherapy in frail older adults with type 2 diabetes mellitus (T2DM) is challenging, recommendations from international guidelines are mainly based on indirect evidence from trials not including frail participants. OBJECTIVE This systematic review investigated the effectiveness and safety of pharmacotherapy in frail older adults with T2DM. MATERIAL AND METHODS Randomized (RCT) and non-randomized prospective clinical trials (non-RCT) were searched in three electronic databases (Medline, Embase, Central) up to October 2018. Trials in older adults with T2DM who were assessed as significantly or severely impaired by defined cut-off scores of assessment instruments on frailty, activities of daily living or physical functional impairment were included. RESULTS Two reviewers independently screened 17,391 references for inclusion and assessed risk of bias with ROBINS‑I. Five non-RCTs and no RCT were identified. Treatment of T2DM without insulin compared to insulin could be associated with increased improvement in cardiac functions in patients with cardiac resynchronization therapy and with decreased falls in frail older women. While better glycemic control with low variability and low HbA1c (hemoglobin A1c) values (

Published
2020
Full Text
View/download PDF

12. A Proposal for the Retrospective Identification and Categorization of Older People With Functional Impairments in Scientific Studies—Recommendations of the Medication and Quality of Life in Frail Older Persons (MedQoL) Research Group

Author

von Arnim, Christine A.F., Bauer, Jürgen M., Bollig, Claudia, Brefka, Simone, Dallmeier, Dhayana, Denkinger, Michael D., Eidam, Annette, Haefeli, Walter E., Lampert, Anette, Mühlbauer, Viktoria, Schönfeldt-Lecuona, Carlos, Seidling, Hanna M., Voigt-Radloff, Sebastian, Onder, Graziano, Petrovic, Mirko, Seibert, Moritz, and Torbahn, Gabriel

Published
2019
Full Text
View/download PDF

15. The Pharmacological Treatment of Arterial Hypertension in Frail, Older Patients: A Systematic Review

Author

Mühlbauer*, Viktoria, Dallmeier*, Dhayana, Brefka, Simone, Bollig, Claudia, Voigt-Radloff, Sebastian, and Denkinger, Michael

Subjects
Original Article
Abstract

BACKGROUND: It is debated whether the treatment goals and decision-making algorithms for elderly patients with hypertension should be the same as those for younger patients. The American and European guidelines leave decisions about antihypertensive treatment in frail, institutionalized patients up to the treating physician. We therefore systematically searched the literature for publications on the phamacotherapy of arterial hypertension in frail patients. METHODS: The MEDLINE, Embase, and Central databases were systematically searched for randomized, controlled trials (RCTs) and non-randomized studies, including observational studies, on the pharmacotherapy of arterial hypertension in elderly patients since the introduction of the concept of frailty, published over the period 1992–2017. RESULTS: Out of 19 282 citations for randomized, controlled trials and 5659 for non-randomized trials and observational studies, four RCTs and three observational studies were included in the further analysis. The included RCTs showed a trend towards a benefit from pharmacotherapy of hypertension in frail patients with respect to mortality, cardiovascular disease, functional status, and quality of life. On the other hand, some of the observational studies indicated a lower rate of falls and lower mortality among patients who received no antihypertensive treatment. CONCLUSION: In view of the conflicting findings of RCTs and non-randomized studies, the lower representation of frail subjects in RCTs, and the high risk of bias in non-randomized studies, the findings of the studies included in this review do not enable the formulation of any strictly evidence-based treatment recommendations. As a rule of thumb, the authors propose that a target systolic blood pressure of

Published
2019

16. Plain Language Summaries von Cochrane Reviews

Author

Bollig, Claudia and Nitschke, Kai

Abstract

Cochrane ist eine internationale not-for-profit-Organisation, deren primäres Ziel die Erstellung, Verbreitung und Aktualisierung von systematischen Übersichtsarbeiten ist. Dabei werden zu einer eindeutigen Fragestellung systematisch alle Studien entsprechend vorab definierten Einschlusskriterien identifiziert, kritisch bewertet und ihre Ergebnisse zusammengefasst, wenn möglich in einer Metaanalyse. Alle aktuellen systematischen Cochrane Übersichtsarbeiten enthalten laienverständliche Zusammenfassungen, so genannte Plain Language Summaries (PLS). Dabei handelt es sich um Zusammenfassungen, die in einfach verständlicher Sprache Methodik und Ergebnisse der Übersichtsarbeiten darstellen. Im Mittelpunkt dieses Vortrags sollen sowohl Hintergründe als auch Hinweise und Erfahrungen zur Erstellung dieser PLS stehen. Darüber hinaus soll die anhaltende Produktion von überflüssigen und niedrig-qualitativen Übersichtsarbeiten thematisiert werden. Als Abschluss wird die bisherige Zusammenarbeit der deutschen klinischen Psychologie mit Cochrane näher beleuchtet.

Published
2018
Full Text
View/download PDF

17. Management and training of linguistic volunteers: a case study of translation at Cochrane Germany

Author

Federici, Federico M., O'Brien, Sharon, Cadwell, Patrick, Bollig, Claudia, Reid, Juliane, Federici, Federico M., O'Brien, Sharon, Cadwell, Patrick, Bollig, Claudia, and Reid, Juliane

Abstract

Cochrane is a global, non-profit organisation that synthesizes health-related research evidence. It established a translation strategy in 2014 to increase the significance of its information beyond the English-speaking world. Under the strategy, translation at Cochrane is achieved mostly through the efforts of linguistic volunteers. Translation in crisis settings, too, relies on the work of volunteers; however, appropriate ways to manage and train these volunteers are unclear. We carried out a study of the case of translation at one part of Cochrane, Cochrane Germany, to learn about the management and training of linguistic volunteers there and in Cochrane more broadly. Thematic analysis of data gathered by the researcher during a two-month secondment to the offices of Cochrane Germany– including data from formal interviews, informal meetings, field notes, a reflective journal, and a large corpus of grey literature – generated three main themes. The themes relate to appropriate conceptualisations of linguistic volunteers, project management in the assurance of quality volunteer work, and feedback as a form of volunteer training. Recommendations are made to apply these lessons learned to future work on crisis translation and for possible improvements to linguistic volunteer management and training at Cochrane.

Published
2019

18. A Proposal for the Retrospective Identification and Categorization of Older People With Functional Impairments in Scientific Studies—Recommendations of the Medication and Quality of Life in Frail Older Persons (MedQoL) Research Group

Author

Brefka, Simone, primary, Dallmeier, Dhayana, additional, Mühlbauer, Viktoria, additional, von Arnim, Christine A.F., additional, Bollig, Claudia, additional, Onder, Graziano, additional, Petrovic, Mirko, additional, Schönfeldt-Lecuona, Carlos, additional, Seibert, Moritz, additional, Torbahn, Gabriel, additional, Voigt-Radloff, Sebastian, additional, Haefeli, Walter E., additional, Bauer, Jürgen M., additional, Denkinger, Michael D., additional, Brefka, Simone, additional, Eidam, Annette, additional, Lampert, Anette, additional, and Seidling, Hanna M., additional

Published
2019
Full Text
View/download PDF

20. Evidence gap on antihyperglycemic pharmacotherapy in frail older adults: A systematic review.

Author

Bollig, Claudia, Torbahn, Gabriel, Bauer, Jürgen, Brefka, Simone, Dallmeier, Dhayana, Denkinger, Michael, Eidam, Annette, Klöppel, Stefan, Zeyfang, Andrej, and Voigt-Radloff, Sebastian

Abstract

Copyright of Zeitschrift für Gerontologie und Geriatrie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2021
Full Text
View/download PDF

22. Deferasirox for managing iron overload in people with thalassaemia

Author

Bollig, Claudia, Schell, Lisa K, Rücker, Gerta, Allert, Roman, Motschall, Edith, Niemeyer, Charlotte M, Bassler, Dirk, Meerpohl, Joerg J, Bollig, Claudia, Schell, Lisa K, Rücker, Gerta, Allert, Roman, Motschall, Edith, Niemeyer, Charlotte M, Bassler, Dirk, and Meerpohl, Joerg J

Published
2017

23. Unterscheiden sich deutsche und deutschsprachige Schweizer Krankenhausapotheker in ihrem Informationsverhalten? Ergebnisse zweier Querschnittsstudien

Author

Bollig, Claudia, Suter, Katja, Günther, Judith, Hoppe-Tichy, Torsten, Antes, Gerd, and Lang, Britta

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund und Fragestellung: Krankenhausapotheker sind für Ärzte, Pflege und Patienten wichtige Ansprechpartner, wenn es um Fragen zur Arzneimitteltherapie geht. Um hochwertige Beratung zur Verfügung zu stellen, brauchen Krankenhausapotheker Zugang zu vertrauenswürdigen, objektiven[zum vollständigen Text gelangen Sie über die oben angegebene URL], Gemeinsam informiert entscheiden; 17. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin

Published
2016
Full Text
View/download PDF

24. RevMan 5 - Einführung in den Review Manager von Cochrane

Author

Toews, Ingrid, Bollig, Claudia, and Sommer, Harriet

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Zielsetzung: In diesem Workshop werden die vielfältigen Funktionen und die zweckmäßige Anwendung der Software Review Manager (RevMan) zur Erstellung eines systematischen Reviews (SR) und zur Durchführung von Metaanalysen (MA) vorgestellt (Version 5.3). Die TeilnehmerInnen erhalten[zum vollständigen Text gelangen Sie über die oben angegebene URL], Gemeinsam informiert entscheiden; 17. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin

Published
2016
Full Text
View/download PDF

26. Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach

Author

Zhang, Yuan, primary, Coello, Pablo Alonso, additional, Brożek, Jan, additional, Wiercioch, Wojtek, additional, Etxeandia-Ikobaltzeta, Itziar, additional, Akl, Elie A., additional, Meerpohl, Joerg J., additional, Alhazzani, Waleed, additional, Carrasco-Labra, Alonso, additional, Morgan, Rebecca L., additional, Mustafa, Reem A., additional, Riva, John J., additional, Moore, Ainsley, additional, Yepes-Nuñez, Juan José, additional, Cuello-Garcia, Carlos, additional, AlRayees, Zulfa, additional, Manja, Veena, additional, Falavigna, Maicon, additional, Neumann, Ignacio, additional, Brignardello-Petersen, Romina, additional, Santesso, Nancy, additional, Rochwerg, Bram, additional, Darzi, Andrea, additional, Rojas, Maria Ximena, additional, Adi, Yaser, additional, Bollig, Claudia, additional, Waziry, Reem, additional, and Schünemann, Holger J., additional

Published
2017
Full Text
View/download PDF

27. Cochrane Reviews are not perfect -- but generally better than non-Cochrane systematic reviews.

Author

Bollig, Claudia, Rüschemeyer, Georg, and Meerpohl, Jörg J.

Subjects
*META-analysis, *SOCIAL services
Abstract

Commentaries Cochrane Reviews sind nicht perfekt -- aber in der Regelbesser als andere Reviews We are grateful to Bergmark and Karlsson for raising thesubject of methodological quality of evidence synthesisin the field of substance misuse. Declaration of conflicting interests: The authors aremembers of Cochrane and authors of several CochraneReviews. [Extracted from the article]

Published
2020
Full Text
View/download PDF

28. Prophylactic antibiotics before cord clamping in cesarean delivery: a systematic review.

Author

Bollig, Claudia, Nothacker, Monika, Lehane, Cornelius, Motschall, Edith, Lang, Britta, Meerpohl, Joerg J., and Schmucker, Christine M.

Subjects
*ANTIBIOTIC prophylaxis, *CRITICAL care medicine, *CESAREAN section, *PREGNANCY complications, *PUERPERAL disorders, *INFECTION prevention, *SURGICAL site infections, *ANTIBIOTICS, *DRUG administration, *INFECTION, *MATERNAL health services, *META-analysis, *PREOPERATIVE care, *UMBILICAL cord, *SYSTEMATIC reviews, *PREVENTION
Abstract

Introduction: The number of clinical trials investigating the optimal timing of prophylactic antibiotics in cesarean section has increased rapidly over the last few years. We conducted a systematic review to inform up-to-date evidence-based guidelines to prevent postpartum infectious morbidity in the mother and rule out any safety issues related to antepartum antibiotic exposure in infants.Material and Methods: Four bibliographic databases were searched for published reports of trials. Ongoing or unpublished studies were searched in Clinicaltrials.gov and the World Health Organization registry platform. Randomized controlled trials comparing antibiotic prophylaxis before and after cord clamping in cesarean section were eligible. Maternal and neonatal outcomes were assessed, and certainty of evidence graded.Results: In total, 18 randomized controlled trials met the inclusion criteria. Those women who received antibiotics preoperatively were 28% (relative risk 0.72, 95% confidence interval 0.56-0.92, nine studies, 4342 women, high quality of evidence) less likely to show infectious morbidity as compared with those who received antibiotics after cord clamping. The risk of endomyometritis and/or endometritis was reduced by 43% (relative risk 0.57, 95% confidence interval 0.40-0.82, 13 studies, 6250 women, high quality of evidence) and the risk of wound infection by 38% (relative risk 0.62, 95% confidence interval 0.47-0.81, 14 studies, 6450 women, high quality of evidence) in those who received antibiotics preoperatively as compared to those who received antibiotics after cord clamping. For other maternal infections no significant differences were identified. The risk for neonatal outcomes, such as deaths attributed to infection, sepsis, neonatal antibiotic treatment, intensive care unit admission or antibiotic-related adverse events, was not found to be different, either clinically or statistically, when antibiotics were given before or after cord clamping (moderate to low quality of evidence).Conclusions: The evidence in favor of prophylactic antibiotic administration before, in comparison with after, cord clamping for major maternal infections was of high quality, meaning that further research would be unlikely to change the confidence in these findings. However, we recommend additional research reflecting the precision of the effect estimates for neonatal outcomes. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

29. Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials

Author

Nguyen, Van Thu, Rivière, Philippe, Ripoll, Pierre, Barnier, Julien, Vuillemot, Romain, Ferrand, Gabriel, Cohen-Boulakia, Sarah, Ravaud, Philippe, Boutron, Isabelle, Alawadhi, Solaf, Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J., Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Riveros, Carolina, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Xia, Jun, Yu, Xuan, Zoletic, Emina, Zweigenbaum, Pierre, Nguyen, Van Thu, Rivière, Philippe, Ripoll, Pierre, Barnier, Julien, Vuillemot, Romain, Ferrand, Gabriel, Cohen-Boulakia, Sarah, Ravaud, Philippe, Boutron, Isabelle, Alawadhi, Solaf, Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J., Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Riveros, Carolina, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Xia, Jun, Yu, Xuan, Zoletic, Emina, and Zweigenbaum, Pierre

Abstract

Objectives: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated. Study Design and Setting: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered. Results: By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1–Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33–67]; 15–163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients. Conclusion: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.

Full Text
View/download PDF

30. Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials

Author

Nguyen, Van Thu, Rivière, Philippe, Ripoll, Pierre, Barnier, Julien, Vuillemot, Romain, Ferrand, Gabriel, Cohen-Boulakia, Sarah, Ravaud, Philippe, Boutron, Isabelle, Alawadhi, Solaf, Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J., Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Riveros, Carolina, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Xia, Jun, Yu, Xuan, Zoletic, Emina, Zweigenbaum, Pierre, Nguyen, Van Thu, Rivière, Philippe, Ripoll, Pierre, Barnier, Julien, Vuillemot, Romain, Ferrand, Gabriel, Cohen-Boulakia, Sarah, Ravaud, Philippe, Boutron, Isabelle, Alawadhi, Solaf, Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J., Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Riveros, Carolina, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Xia, Jun, Yu, Xuan, Zoletic, Emina, and Zweigenbaum, Pierre

Abstract

Objectives: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated. Study Design and Setting: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered. Results: By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1–Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33–67]; 15–163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients. Conclusion: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.

Full Text
View/download PDF

31. Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials

Author

Nguyen, Van Thu, Rivière, Philippe, Ripoll, Pierre, Barnier, Julien, Vuillemot, Romain, Ferrand, Gabriel, Cohen-Boulakia, Sarah, Ravaud, Philippe, Boutron, Isabelle, Alawadhi, Solaf, Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J., Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Riveros, Carolina, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Xia, Jun, Yu, Xuan, Zoletic, Emina, Zweigenbaum, Pierre, Nguyen, Van Thu, Rivière, Philippe, Ripoll, Pierre, Barnier, Julien, Vuillemot, Romain, Ferrand, Gabriel, Cohen-Boulakia, Sarah, Ravaud, Philippe, Boutron, Isabelle, Alawadhi, Solaf, Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J., Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Riveros, Carolina, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Xia, Jun, Yu, Xuan, Zoletic, Emina, and Zweigenbaum, Pierre

Abstract

Objectives: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated. Study Design and Setting: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered. Results: By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1–Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33–67]; 15–163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients. Conclusion: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.

Full Text
View/download PDF

32. Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials

Author

Nguyen, Van Thu, Rivière, Philippe, Ripoll, Pierre, Barnier, Julien, Vuillemot, Romain, Ferrand, Gabriel, Cohen-Boulakia, Sarah, Ravaud, Philippe, Boutron, Isabelle, Alawadhi, Solaf, Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J., Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Riveros, Carolina, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Xia, Jun, Yu, Xuan, Zoletic, Emina, Zweigenbaum, Pierre, Nguyen, Van Thu, Rivière, Philippe, Ripoll, Pierre, Barnier, Julien, Vuillemot, Romain, Ferrand, Gabriel, Cohen-Boulakia, Sarah, Ravaud, Philippe, Boutron, Isabelle, Alawadhi, Solaf, Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J., Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Riveros, Carolina, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Xia, Jun, Yu, Xuan, Zoletic, Emina, and Zweigenbaum, Pierre

Abstract

Objectives: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated. Study Design and Setting: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered. Results: By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1–Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33–67]; 15–163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients. Conclusion: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.

Full Text
View/download PDF

33. Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials

Author

Nguyen, Van Thu, Rivière, Philippe, Ripoll, Pierre, Barnier, Julien, Vuillemot, Romain, Ferrand, Gabriel, Cohen-Boulakia, Sarah, Ravaud, Philippe, Boutron, Isabelle, Alawadhi, Solaf, Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J., Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Riveros, Carolina, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Xia, Jun, Yu, Xuan, Zoletic, Emina, Zweigenbaum, Pierre, Nguyen, Van Thu, Rivière, Philippe, Ripoll, Pierre, Barnier, Julien, Vuillemot, Romain, Ferrand, Gabriel, Cohen-Boulakia, Sarah, Ravaud, Philippe, Boutron, Isabelle, Alawadhi, Solaf, Amer-Yahia, Sihem, Ávila, Camila, Bafeta, Aïda, Baudry, Julia, Bollig, Claudia, Bonnet, Hillary, Bouet, Marinette, Cabanac, Guillaume, Chaimani, Anna, Chavalarias, David, Chen, Yaolong, Chevance, Astrid, Coquery, Emmanuel, Conil, Francoise, Davidson, Mauricia, De Nale, Laura, Devane, Declan, Diard, Elise, Doreau, Bastien, Evrenoglou, Theodoros, Fabri, Alice, Feron, Gilles, Fezeu, Leopold, Fouet, Mathilde, El Chall, Lina Ghosn, Graña, Carolina, Grasselli, Giacomo, Grolleau, François, Hacid, Mohand-Said, Haddy, Loubna, Hansen, Camilla, Hohlfeld, Ameer, Hróbjartsson, Asbjørn, Julia, Chantal, Mavridis, Dimitris, Meerpohl, Joerg J., Meyer, Brice, Naidoo, Nivantha, Thu, Van Nguyen, Oikonomidi, Theodora, Pienaar, Elizabeth, Quirke, Fiona, Rada, Gabriel, Riveros, Carolina, Sauvant, Marie, Schmucker, Christine, Toumani, Farouk, Tovey, David, Xia, Jun, Yu, Xuan, Zoletic, Emina, and Zweigenbaum, Pierre

Abstract

Objectives: Researchers worldwide are actively engaging in research activities to search for preventive and therapeutic interventions against coronavirus disease 2019 (COVID-19). Our aim was to describe the planning of randomized controlled trials (RCTs) in terms of timing related to the course of the COVID-19 epidemic and research question evaluated. Study Design and Setting: We performed a living mapping of RCTs registered in the WHO International Clinical Trials Registry Platform. We systematically search the platform every week for all RCTs evaluating preventive interventions and treatments for COVID-19 and created a publicly available interactive mapping tool at https://covid-nma.com to visualize all trials registered. Results: By August 12, 2020, 1,568 trials for COVID-19 were registered worldwide. Overall, the median ([Q1–Q3]; range) delay between the first case recorded in each country and the first RCT registered was 47 days ([33–67]; 15–163). For the 9 countries with the highest number of trials registered, most trials were registered after the peak of the epidemic (from 100% trials in Italy to 38% in the United States). Most trials evaluated treatments (1,333 trials; 85%); only 223 (14%) evaluated preventive strategies and 12 postacute period intervention. A total of 254 trials were planned to assess different regimens of hydroxychloroquine with an expected sample size of 110,883 patients. Conclusion: This living mapping analysis showed that COVID-19 trials have relatively small sample size with certain redundancy in research questions. Most trials were registered when the first peak of the pandemic has passed.

Full Text
View/download PDF

34. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations : GRADE-ADOLOPMENT

Author

Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística, Schünemann, Holger J., Wiercioch, Wojtek, Brozek, Jan, Etxeandia Ikobaltzeta, Itziar, Mustafa, Reem A., Manja, Veena, Brignardello Petersen, Romina, Neumann, Ignacio, Falavigna, Maicon, Alhazzani, Waleed, Santesso, Nancy, Zhang, Yuan, Meerpohl, Jörg J., Morgan, Rebecca L., Rochwerg, Bram, Darzi, Andrea, Rojas Reyes, María Ximena, Carrasco Labra, Alonso, Adi, Yaser, AlRayees, Zulfa, Riva, John, Bollig, Claudia, Moore, Ainsley, Yepes Nuñez, Juan José, Cuello, Carlos, Waziry, Reem, Akl, Elie A., Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística, Schünemann, Holger J., Wiercioch, Wojtek, Brozek, Jan, Etxeandia Ikobaltzeta, Itziar, Mustafa, Reem A., Manja, Veena, Brignardello Petersen, Romina, Neumann, Ignacio, Falavigna, Maicon, Alhazzani, Waleed, Santesso, Nancy, Zhang, Yuan, Meerpohl, Jörg J., Morgan, Rebecca L., Rochwerg, Bram, Darzi, Andrea, Rojas Reyes, María Ximena, Carrasco Labra, Alonso, Adi, Yaser, AlRayees, Zulfa, Riva, John, Bollig, Claudia, Moore, Ainsley, Yepes Nuñez, Juan José, Cuello, Carlos, Waziry, Reem, and Akl, Elie A.

35. Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach

Author

Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística, Zhang, Yuan, Coello, Pablo Alonso, Brożek, Jan, Wiercioch, Wojtek, Etxeandia-Ikobaltzeta, Itziar, Akl, Elie A., Meerpohl, Joerg J., Alhazzani, Waleed, Carrasco Labra, Alonso, Morgan, Rebecca L., Mustafa, Reem A., Riva, John J., Moore, Ainsley, Yepes Nuñez, Juan José, Cuello Garcia, Carlos, AlRayees, Zulfa, Manja, Veena, Falavigna, Maicon, Neumann, Ignacio, Brignardello Petersen, Romina, Santesso, Nancy, Rochwerg, Bram, Darzi, Andrea, Rojas Reyes, Maria Ximena, Adi, Yaser, Bollig, Claudia, Waziry, Reem, Schünemann, Holger J., Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística, Zhang, Yuan, Coello, Pablo Alonso, Brożek, Jan, Wiercioch, Wojtek, Etxeandia-Ikobaltzeta, Itziar, Akl, Elie A., Meerpohl, Joerg J., Alhazzani, Waleed, Carrasco Labra, Alonso, Morgan, Rebecca L., Mustafa, Reem A., Riva, John J., Moore, Ainsley, Yepes Nuñez, Juan José, Cuello Garcia, Carlos, AlRayees, Zulfa, Manja, Veena, Falavigna, Maicon, Neumann, Ignacio, Brignardello Petersen, Romina, Santesso, Nancy, Rochwerg, Bram, Darzi, Andrea, Rojas Reyes, Maria Ximena, Adi, Yaser, Bollig, Claudia, Waziry, Reem, and Schünemann, Holger J.

Catalog

Books, media, physical & digital resources
See catalog results